ChemoRT Then Immunochemotherapy Then Surgery Promising in Unresectable Esophageal Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 18, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Nov. 18, 2024 -- For patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC), chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and then surgery is promising, according to a study published online Nov. 15 in Clinical Cancer Research.

Xin Wang, from the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, and colleagues examined the safety and efficacy of CRT followed by iCT and surgery for unresectable locally advanced ESCC. Patients received radiotherapy and nab-paclitaxel plus cisplatin for five weeks, followed by tislelizumab plus chemotherapy (nab-paclitaxel and cisplatin) for two 21-day cycles. Patients who converted to resectable then underwent surgery. One-year progression-free survival (PFS) was the primary end point.

Thirty patients were enrolled and underwent CRT; 24 of these received iCT. The researchers found that 20 patients (66.7 percent) achieved resectability (R0: 95.2 percent). The one-year PFS rate was 79.4 percent, and the overall survival rate was 89.6 percent. Significantly longer PFS and overall survival were exhibited by the R0 resection group (hazard ratios, 0.28 and 0.18, respectively). Eleven patients (36.7 percent) had grade 3 to 4 adverse events, and five of those receiving iCT had immune-related pneumonitis (20.8 percent). There was an association seen for post-CRT minimal residual disease before surgery with unfavorable PFS and overall survival.

"The neoadjuvant treatment approach we tested has the potential to make initially unresectable tumors resectable, giving patients the opportunity to have a durable cancer-free state," Li said in a statement. "Our trial clearly demonstrated the effectiveness of combining chemoradiotherapy, chemoimmunotherapy, and surgery compared to nonsurgical management alone. We were confident in potential benefits of adding immunotherapy to chemoradiotherapy, but the remarkable pathologic complete response and the strong survival outcomes far exceeded our expectations."

Two authors disclosed ties to Nanjing Geneseeq Technology.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-11-19 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords